Back
Compare AU
Compare STW vs. CURE
Compare shares and ETFs on the ASX that you can trade on Pearler.
Overview
When it comes to investing in the Australian stock market, Exchange-Traded Funds (ETFs) are a popular choice. Two well-known options in the Australian Securities Exchange (ASX) are the State Street SPDR S&P/ASX 200 ETF (STW) and the Global X S&P Biotech ETF (CURE). In this comparison, we'll delve into these ETFs across various dimensions to help you make an informed investment decision.
Community Stats
STW | CURE | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 411 | 69 |
Median incremental investment | $1,000.00 | $683.16 |
Median investment frequency | Monthly | Monthly |
Median total investment | $5,159.70 | $2,329.60 |
Average age group | > 35 | > 35 |
Key Summary
STW | CURE | |
|---|---|---|
Strategy | STW.AX was created on 2001-08-24 by State Street . The fund's investment portfolio concentrates primarily on large cap equity. The ETF currently has 6541.67m in AUM and 204 holdings. The Investment Objective of State Street SPDR S&P/ASX 200 ETF is to match the performance of its Index before fees and other costs. | CURE.AX was created on 2018-11-08 by Global X. The fund's investment portfolio concentrates primarily on health care equity. The ETF currently has 41.56m in AUM and 143 holdings. The Fund aims to provide investors with a return that (before fees and expenses) tracks the performance of the S&P Biotechnology Select Industry Index. |
Top 3 holdings | BHP Group Ltd (12.03 %) Commonwealth Bank of Australia (9.89 %) Westpac Banking Corp (4.39 %) | Apogee Therapeutics Inc (1.61 %) Spyre Therapeutics Inc (1.34 %) Oruka Therapeutics Inc (1.34 %) |
Top 3 industries | Financials (54.95 %) Materials (16.65 %) Health Care (10.33 %) | Health Care (100.00 %) Other (10.24 %) |
Top 3 countries | Australia (95.26 %) United States (3.26 %) United Kingdom of Great Britain and Northern Ireland (0.54 %) | United States (96.62 %) United Kingdom of Great Britain and Northern Ireland (1.35 %) Switzerland (1.13 %) |
Management fee | 0 % | 0.45 % |
Key Summary
STW | CURE | |
|---|---|---|
Issuer | State Street | Global X |
Tracking index | S&P ASX 200 | S&P Biotechnology Select Industry |
Asset class | ETF | ETF |
Management fee | 0 % | 0.45 % |
Price | $78.98 | $73.42 |
Size | $6.623 billion | $43.170 million |
10Y return | 61.65 % | N/A |
Annual distribution yield (5Y) | 4.17 % | 5.08 % |
Market | ASX | ASX |
First listed date | 27/08/2001 | 12/11/2018 |
Purchase fee | $6.50 | $6.50 |
Community Stats
STW | CURE | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 411 | 69 |
Median incremental investment | $1,000.00 | $683.16 |
Median investment frequency | Monthly | Monthly |
Median total investment | $5,159.70 | $2,329.60 |
Average age group | > 35 | > 35 |
Pros and Cons
STW | CURE | |
|---|---|---|
Pros |
|
|
Cons |
|
|
STW | CURE |
|---|---|
Higher exposure to AU market | Lower exposure to AU market |
Lower exposure to US market | Higher exposure to US market |
Lower management fee | Higher management fee |
Higher price growth | Lower price growth |
Lower distribution yield | Higher distribution yield |